BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28035066)

  • 1. Estradiol shows anti-skin cancer activities through decreasing MDM2 expression.
    Li L; Feng J; Chen Y; Li S; Ou M; Sun W; Tang L
    Oncotarget; 2017 Jan; 8(5):8459-8474. PubMed ID: 28035066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression.
    Dar AA; Majid S; Rittsteuer C; de Semir D; Bezrookove V; Tong S; Nosrati M; Sagebiel R; Miller JR; Kashani-Sabet M
    J Natl Cancer Inst; 2013 Mar; 105(6):433-42. PubMed ID: 23365201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
    Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
    Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of hnRNPA1 promotes cell invasion by inducing EMT in gastric cancer.
    Chen Y; Liu J; Wang W; Xiang L; Wang J; Liu S; Zhou H; Guo Z
    Oncol Rep; 2018 Apr; 39(4):1693-1701. PubMed ID: 29484423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo.
    Lu X; Yan C; Huang Y; Shi D; Fu Z; Qiu J; Yin Y
    Oncotarget; 2016 Jun; 7(24):37177-37191. PubMed ID: 27184007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetracaine hydrochloride induces cell cycle arrest in melanoma by downregulating hnRNPA1.
    Huang X; Chen Y; Yi J; Yi P; Jia J; Liao Y; Feng J; Jiang X
    Toxicol Appl Pharmacol; 2022 Jan; 434():115810. PubMed ID: 34822839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2.
    Wang W; Zhang X; Qin JJ; Voruganti S; Nag SA; Wang MH; Wang H; Zhang R
    PLoS One; 2012; 7(7):e41586. PubMed ID: 22911819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.
    Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L
    J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
    Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
    Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient receptor potential cation 3 channel regulates melanoma proliferation and migration.
    Oda K; Umemura M; Nakakaji R; Tanaka R; Sato I; Nagasako A; Oyamada C; Baljinnyam E; Katsumata M; Xie LH; Narikawa M; Yamaguchi Y; Akimoto T; Ohtake M; Fujita T; Yokoyama U; Iwatsubo K; Aihara M; Ishikawa Y
    J Physiol Sci; 2017 Jul; 67(4):497-505. PubMed ID: 27613608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 and PSMA Play Inhibitory Roles in Metastatic Breast Cancer Cells Through Regulation of Matrix Metalloproteinases.
    Bradbury R; Jiang WG; Cui YX
    Anticancer Res; 2016 Mar; 36(3):1143-51. PubMed ID: 26977010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell.
    Li X; Li Z; Li X; Liu B; Liu Z
    BMC Cancer; 2017 May; 17(1):357. PubMed ID: 28532456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
    Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
    Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
    Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway.
    Qin G; Xu F; Qin T; Zheng Q; Shi D; Xia W; Tian Y; Tang Y; Wang J; Xiao X; Deng W; Wang S
    Oncotarget; 2015 Dec; 6(39):41794-808. PubMed ID: 26540629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNAi-mediated human Nestin silence inhibits proliferation and migration of malignant melanoma cells by G
    Yang XH; Xia T; Zhang J; Yang SF; Tang HX; Tang T; Huang ZC; Zhong YS; He F; Xiang AP
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):895-903. PubMed ID: 29270750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene.
    Kong Y; Lu ZL; Wang JJ; Zhou R; Guo J; Liu J; Sun HL; Wang H; Song W; Yang J; Xu HX
    Oncol Rep; 2016 Sep; 36(3):1447-56. PubMed ID: 27432230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
    Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
    J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.